Advanced NSCLC patients with no EGFR (Epidermal Growth Factor Receptor) or ALK (Anaplastic Lymphoma Kinase) genetic alterations were monitored for 3 years. This evidence concerns the gene ALK and non-small cell lung carcinoma.